Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hemat...
November 28 2016 - 8:30AM
Business Wire
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology
company developing novel anti-infectives including immunotherapies,
today announced that data from preclinical and clinical studies
evaluating its novel echinocandin antifungal CD101 will be
presented at the 58th American Society of Hematology (ASH) Annual
Meeting and Exposition taking place in San Diego from December 3-6,
2016. CD101 is Cidara’s lead antifungal drug candidate and the only
long-acting antifungal in the echinocandin class.
“Patients with blood cancers and those undergoing
transplantation are at much higher risk for opportunistic fungal
infections, often the cause of significant morbidity and
mortality,” said Jeffrey Stein, Ph.D., president and chief
executive officer of Cidara. “We are pleased to be sharing data at
this year’s ASH meeting that demonstrate the potential of our novel
compound CD101 to treat and prevent deadly fungal infections in
blood cancer patients.”
CD101 data accepted for presentation at this year’s ASH Annual
Meeting comprise the following:
- Two poster presentations evaluating the
efficacy of CD101 for the treatment and prevention of invasive
fungal infections due to the pathogens, Candida, Aspergillus and
Pneumocystis.
- A poster presentation summarizing
results from the successful Phase 1 clinical trial of CD101 IV,
demonstrating the safety and pharmacokinetics of single and
multiple weekly dosing regimens.
Approximately 97,000 Americans die from hospital-related fungal
infections each year and 90 percent of these infections are caused
by two common fungi, Candida and Aspergillus. Systemic fungal
infections typically affect patients whose immune systems have been
compromised, such as patients undergoing organ or bone marrow
transplantation or chemotherapy including patients with hematologic
malignancies. Pneumocystis is another serious fungal infection that
commonly afflicts people with weakened immune systems.
“Invasive fungal infections remain a significant threat in
patients with hematological cancer and in transplant recipients.
Although significant progress has been made in diagnostics and the
introduction of new agents, significant challenges remain,” said
Dimitrios P. Kontoyiannis, M.D., of The University of Texas MD
Anderson Cancer Center. “Current antifungals have several issues
with suboptimal pharmacokinetics, frequent drug-to-drug
interactions and contraindications with chemotherapy or
immunosuppressants, toxicity and suboptimal efficacy, especially as
fungal resistance is on the rise. There is an unmet need for new
antifungal therapies that are safe and effective with low
toxicity.”
Details for the Cidara ASH 2016 presentations are as
follows:
Saturday, December 3 – Session 721: Clinical Allogeneic
Transplantation: Conditioning Regimens, Engraftment, and Acute
Transplant Toxicities - Poster I (5:30 p.m. - 7:30 p.m. PT, Hall
GH)
- Pharmacokinetics, Safety, and Target
Attainment of Single and Multiple Doses of CD101 IV; T Sandison,
et. al. #2197
Sunday, December 4 – Session 721: Clinical Allogeneic
Transplantation: Conditioning Regimens, Engraftment, and Acute
Transplant Toxicities - Poster II (6:00 p.m. - 8:00 p.m. PT, Hall
GH)
- Efficacy of CD101, a Novel
Echinocandin, in Mouse Models of Aspergillosis and Azole-Resistant
Disseminated Candidiasis; V. Ong, et. al. #3400
- Efficacy of CD101, a Novel
Echinocandin, in Prevention of Pneumocystis Pneumonia (PCP):
Thwarting the Biphasic Life Cycle of Pneumocystis; M. Cushion, et.
al. #3396
Abstracts can be found at www.hematology.org and copies of these
poster presentations will also be available on the Cidara website
following the meeting: http://www.Cidara.com/
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
CD101, through Phase 2 studies in two indications and developing
CD201, its bispecific antimicrobial immunotherapy, for the
treatment of multi-drug resistant bacterial infections. CD101 IV
has enhanced potency and is the only once-weekly therapy intended
for the treatment and prevention of life-threatening invasive
fungal infections. CD101 topical is the first and only agent of its
class being studied for the treatment and prevention of
vulvovaginal candidiasis (VVC), a prevalent mucosal infection.
CD201 is the first drug candidate selected from Cidara’s novel
Cloudbreak™ platform, the first immunotherapy discovery platform
designed specifically to create compounds that direct a patient's
immune cells to attack and eliminate bacterial, fungal or viral
pathogens. Cidara is headquartered in San Diego, California. For
more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effectiveness, safety, long-acting nature, anticipated human
dosing and other attributes of CD101, and its potential to treat
infections, including infections associated with hematologic
malignancies and transplantation. Risks that contribute to the
uncertain nature of the forward-looking statements include: the
success and timing of Cidara’s preclinical studies and clinical
trials; regulatory developments in the United States and foreign
countries; changes in Cidara’s plans to develop and commercialize
its product candidates; Cidara’s ability to obtain additional
financing; Cidara’s ability to obtain and maintain intellectual
property protection for its product candidates; and the loss of key
scientific or management personnel. These and other risks and
uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161128005107/en/
INVESTOR CONTACT:Westwicke Partners, LLCRobert H. Uhl,
858-356-5932Managing Directorrobert.uhl@westwicke.comorMEDIA
CONTACT:Sam Brown Inc.Christy Curran,
615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024